Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg ...

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

Kyverna Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product candidate, KYV-101, is a CAR ...

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

This oncology device innovator, known for its tumor-treating technologies, reported a notable insider sale in its latest SEC filing.

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.